All In Biotech

NDA 050587 · Merck

Primaxin

Cilastatin Sodium, Imipenem · Intravenous

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jan 30, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Nov 26, 1985

Approved uses

2

Original approval plus efficacy supplements

Registered trials

65

21 Phase 3, 2 recruiting

FAERS reports

2,371

1,943 serious, 560 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 5, 2024.

PRIMAXIN for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use: PRIMAXIN is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). PRIMAXIN is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage: To reduce the development of drug resistant bacteria and maintain the effectiveness of PRIMAXIN and other antibacterial drugs, PRIMAXIN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). 1.1 Lower Respiratory Tract Infections PRIMAXIN for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli , Haemophilus influenzae , Haemophilus parainfluenzae , Klebsiella species, Serratia marcescens. 1.2 Urinary Tract Infections (complicated and uncomplicated) PRIMAXIN is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of Enterococcus faecalis , Staphylococcus aureus (penicillinase-producing isolates),...

Mechanism: PRIMAXIN is a combination of imipenem and cilastatin. Imipenem is a penem antibacterial drug [see Microbiology (12.4) ] . Cilastatin is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 8, 1998 Supplement 48 · Efficacy LabelLetter
  • Nov 26, 1985 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review Review
2 products under this application
  • PRIMAXIN · CILASTATIN SODIUM EQ 250MG BASE/VIAL; IMIPENEM 250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued
  • PRIMAXIN · CILASTATIN SODIUM EQ 500MG BASE/VIAL; IMIPENEM 500MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Cilastatin" as an intervention, any sponsor and status, largest first.

All 65 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication221
  • convulsion188
  • drug ineffective127
  • pyrexia122
  • pneumonia116
  • off label use115
  • sepsis103
  • death91
  • renal failure74
  • septic shock74
  • multi-organ failure72
  • rash72

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004193
2005202
2006175
2007172
2008180
2009211
2010152
2011155
2012163
201325
201427
201519
201629
201744
201865
201981
202056
202185
202267
202399
2024113
202538
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jan 8, 2026

    Primaxin, Injection, 500mg (NDC 0006-3516-59). To be discontinued approximately 11/30/2026

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Primaxin (Imipenem/Cilastatin Sodium)

2024 spending

$19K

Beneficiaries

15

38 claims

Per beneficiary

$1,240

$9.65 per unit

View as table
YearSpending
2020$45,132
2021$52,933
2022$41,121
2023$21,562
2024$18,604

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 338 on PubMed

Sponsor: Merck

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.